Kalydeco (IVacaftor) Patent Expiration, LOE Window & CMS Spending

Kalydeco (IVacaftor) by Vertex Pharmaceuticals: FDA Orange Book core substance LOE 2027-11-20 (last listed 2030-02-13), 0 AB generics, $104.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVertex Pharmaceuticals
FDA Application & PathwayN203188 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-11-20
Last Listed Patent or Exclusivity Date2030-02-13
Orange Book Patents (*PED Extensions)18 patents (9 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$104.7M
2024 Medicare Part D Spend$28.7M
2024 Medicaid Spend$75.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.